Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 20;128(24):3317-23.
doi: 10.4103/0366-6999.171424.

Mid- to Long-term Clinical Outcomes of Hancock II Bioprosthesis in Chinese Population

Yin Wang, Si Chen, Xing-Jian Hu, Jia-Wei Shi, Nian-Guo Dong  1
Affiliations

Mid- to Long-term Clinical Outcomes of Hancock II Bioprosthesis in Chinese Population

Yin Wang et al. Chin Med J (Engl). .

Abstract

Background: Compared to the Western countries, Chinese patients present a special primary disease spectrum, diverse valvular pathogenesis, and different postoperational anticoagulation strategy. This research aimed to evaluate the mid- to long-term clinical performance of Hancock II bioprosthesis in the Chinese population.

Methods: This study retrospectively reviewed all patients who received surgical treatments with at least one Hancock II bioprosthesis implantation from January 2004 to December 2013 at a single center in China. Totally 647 patients were included in the clinical evaluation, and 629 patients were successfully discharge, among whom 605 patients were completely followed-up. The follow-up rate was 96.2%. The mean and median follow-up time was 62.0 ± 59.0 and 56.0 months, respectively. Postoperative outcomes of survival rates, reoperations and valve related morbidities were assessed. Continuous and categorical variables were compared using the t -test and Chi-square test, respectively. Survival and freedom from adverse events were calculated by using a Kaplan-Meier method.

Results: The overall in-hospital mortality was 2.8% (18/647) while there were 34 deaths (5.6%, 34/605) in the follow-up stage after discharge. The overall survival rate was 94.6% and 82.7% at 5 years and 10 years, respectively. The cumulative survival rate of 10 years was 82.8% in AVR group, 84.4% in MVR group, and 78.4% in DVR group. The overall rate of freedom from reoperations was 95.5% at 5 years and 86.8% at 10 years. The freedom from reoperation at 10 years was 87.0%, 88.1%, and 84.0% in AVR, MVR, and DVR group, respectively. The freedom from morbidities at 10 years was: 90.3% for thromboembolism, 95.2% for hemorrhage, 97.5% for prosthesis endocarditis, 95.9% for paravalvular leak, and 94.6% for structural valve deterioration, respectively.

Conclusions: Hancock II bioprosthesis exhibited a satisfactory mid- to long-term durability and promising clinical performance in the Chinese population. The occurrence rates of death and other adverse events in this single-center study were overall coincident and quite acceptable when compared with existing data.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Variations of annual cases (a) and proportion (b) of patients with Hancock II bioprosthesis replacement during the last decade.
Figure 2
Figure 2
Survival curve of the overall cohort.
Figure 3
Figure 3
Survival curves according to the type of operation.
Figure 4
Figure 4
Curve of freedom from reoperations of the overall cohort.
Figure 5
Figure 5
Curve of freedom from reoperations according to the type of operation.
See this image and copyright information in PMC

References

    1. Bortolotti U, Milano A, Mossuto E, Mazzaro E, Thiene G, Casarotto D. Porcine valve durability: A comparison between Hancock standard and Hancock II bioprostheses. Ann Thorac Surg. 1995;60(2 Suppl):S216–20. - PubMed
    1. Valfrè C, Ius P, Minniti G, Salvador L, Bottio T, Cesari F, et al. The fate of Hancock II porcine valve recipients 25 years after implant. Eur J Cardiothorac Surg. 2010;38:141–6. - PubMed
    1. Une D, Ruel M, David TE. Twenty-year durability of the aortic Hancock II bioprosthesis in young patients: Is it durable enough? Eur J Cardiothorac Surg. 2014;46:825–30. - PubMed
    1. Rizzoli G, Mirone S, Ius P, Polesel E, Bottio T, Salvador L, et al. Fifteen-year results with the Hancock II valve: A multicenter experience. J Thorac Cardiovasc Surg. 2006;132:602–9. - PubMed
    1. Chan V, Kulik A, Tran A, Hendry P, Masters R, Mesana TG, et al. Long-term clinical and hemodynamic performance of the Hancock II versus the Perimount aortic bioprostheses. Circulation. 2010;122(11 Suppl):S10–6. - PubMed

Publication types